1. Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Christian Hampel 
European Urology Supplements 
Volume 6, Issue 5, Pages (March 2007)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Treatment persistence rates over time in 231 women with detrusor instability or low compliance on antimuscarinic therapy. Numbers over bars represent number of women receiving therapy at each time point [1].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
Treatment persistence, patient compliance and drug-switching rates after 12 mo of therapy with tolterodine or oxybutinin. ***p<0.001 vs. oxybutinin; †patients switching to alternative agents for treatment of overactive bladder [4].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Mean rates of compliance with therapy as daily dose frequency increases. *p<0.01, **p<0.001 vs. once-daily dosing [11].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
Adverse events reported in randomised clinical trials of antimuscarinic agents 1996–2004. Reprinted from Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5–26, © 2005, with permission from the European Association of Urology.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions